[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@ThomasFiligrane](/creator/twitter/ThomasFiligrane) "🚨BTIG maintains $HUMA at BUY trimming target to $X (from $7). Thats still a +255 % upside from todays $XXXX level. 📈🫣 BTIG Analyst Ryan Zimmerman remains bullish on Humacytes bioengineered vessel (ATEV) platform a first-in-class regenerative medicine tech despite dilution from the recent $60M raise. #HUMA #biotech #investing #stocks #regenerativemedicine" [X Link](https://x.com/ThomasFiligrane/status/1977770813097992378) [@ThomasFiligrane](/creator/x/ThomasFiligrane) 2025-10-13T16:18Z XXX followers, 2203 engagements "🚨 WHEN A GLOBAL LEADER HIGHLIGHTS $HUMA IN ITS REPORT Fresenius Medical Care ($FMS) the worlds dialysis giant mentioned Humacyte in its Q2 2025 earnings presentation. 👉 The positive impact of the Humacyte remeasurement is clearly highlighted in their investor slides. 💡 Translation: - They hold $HUMA and are keeping their position. - They are publicly valuing this partnership/investment. - This isnt just an accounting line its a signal of confidence in the companys potential. 📊 When a global leader talks about you in their earnings its never by accident. $FMS $HUMA" [X Link](https://x.com/ThomasFiligrane/status/1954625591770075192) [@ThomasFiligrane](/creator/x/ThomasFiligrane) 2025-08-10T19:27Z XXX followers, 2554 engagements "🚨 HUMACYTE: WHEN OVERVALUED ACTUALLY MEANS FULL OF POTENTIAL Recently Simply Wall Street published a note suggesting that Humacyte (HUMA) is overvalued citing a price-to-book (P/B) ratio of 69.4x far above the biotech industry average of around 2.6x. At first glance that reasoning sounds logical: the higher the ratio the more expensive the company appears relative to its tangible assets. But in Humacytes case that argument doesnt really make sense. 🧬 A biotech not a bank Humacyte isnt an industrial or financial company with factories and buildings on its balance sheet. Its a pre-commercial" [X Link](https://x.com/ThomasFiligrane/status/1979892359925276966) [@ThomasFiligrane](/creator/x/ThomasFiligrane) 2025-10-19T12:48Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@ThomasFiligrane
"🚨BTIG maintains $HUMA at BUY trimming target to $X (from $7). Thats still a +255 % upside from todays $XXXX level. 📈🫣 BTIG Analyst Ryan Zimmerman remains bullish on Humacytes bioengineered vessel (ATEV) platform a first-in-class regenerative medicine tech despite dilution from the recent $60M raise. #HUMA #biotech #investing #stocks #regenerativemedicine"
X Link @ThomasFiligrane 2025-10-13T16:18Z XXX followers, 2203 engagements
"🚨 WHEN A GLOBAL LEADER HIGHLIGHTS $HUMA IN ITS REPORT Fresenius Medical Care ($FMS) the worlds dialysis giant mentioned Humacyte in its Q2 2025 earnings presentation. 👉 The positive impact of the Humacyte remeasurement is clearly highlighted in their investor slides. 💡 Translation: - They hold $HUMA and are keeping their position. - They are publicly valuing this partnership/investment. - This isnt just an accounting line its a signal of confidence in the companys potential. 📊 When a global leader talks about you in their earnings its never by accident. $FMS $HUMA"
X Link @ThomasFiligrane 2025-08-10T19:27Z XXX followers, 2554 engagements
"🚨 HUMACYTE: WHEN OVERVALUED ACTUALLY MEANS FULL OF POTENTIAL Recently Simply Wall Street published a note suggesting that Humacyte (HUMA) is overvalued citing a price-to-book (P/B) ratio of 69.4x far above the biotech industry average of around 2.6x. At first glance that reasoning sounds logical: the higher the ratio the more expensive the company appears relative to its tangible assets. But in Humacytes case that argument doesnt really make sense. 🧬 A biotech not a bank Humacyte isnt an industrial or financial company with factories and buildings on its balance sheet. Its a pre-commercial"
X Link @ThomasFiligrane 2025-10-19T12:48Z XXX followers, XXX engagements
/creator/twitter::1042346198353403905/posts